EUVIMEDEUVIMED entdecken
Open Access

No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19

Moshe Rogosnitzky iD, Esther Berkowitz iD, Alejandro R Jadad iD

JMIRx Med · 2020

DOI: 10.2196/19583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIRx Med, 2020. Verfasst von Moshe Rogosnitzky und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medinsight Research Institute Rehovot Israel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real-world drug repurposing—the immediate “off-label” prescribing of drugs to address urgent clinical needs—is an indispensable strategy gaining rapid traction in the current COVID-19 crisis. Although off-label prescribing (ie, for a nonapproved indication) is legal in most countries, it tends to shift the burden of liability and cost to physicians and patients, respectively. Nevertheless, in urgent public health crises, it is often the only realistic source of a meaningful potential solution. To be considered for real-world repurposing, drug candidates should ideally have a track record of safety, affordability, and wide accessibility. Although thousands of such drugs are already available, the absence of a central repository of off-label uses presents a barrier to the immediate identification and selection of the safest, potentially useful interventions. Using the current COVID-19 pandemic as an example, we provide a glimpse at the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and pleiotropically target the underlying pathophysiology that makes COVID-19 so dangerous. Having previously fast-tracked this paper to publication in summary form, we now expand on why cimetidine/famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate/bezafibrate (cholesterol/triglyceride-lowering agents), and sildenafil (phosphodiesterase-5 inhibitor) are worth considering for patients with COVID-19 based on their antiviral, anti-inflammatory, renoprotective, cardioprotective, and anticoagulation properties. These examples also reveal the unlimited opportunity to future-proof public health by proactively mining, synthesizing, and cataloging the off-label treatment opportunities of thousands of safe, well-established, and affordable generic drugs.

Schlagwörter

Stichwörter der Autor:innen

COVID-19bezafibratecimetidinedipyridamoledrug repurposingfamotidinefenofibratefibrateshistamine type-2 receptor antagonistssildenafil

Autor:innen und Institutionen

  • Medinsight Research Institute Rehovot Israel.
  • Program in Impactful Giving Dalla Lana School of Public Health University of Toronto Toronto, ON Canada.

ORCID-Profile: Moshe Rogosnitzky, Esther Berkowitz, Alejandro R Jadad

Zitieren

APA

Rogosnitzky, M., Berkowitz, E., & Jadad, A. R. (2020). No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. JMIRx Med. https://doi.org/10.2196/19583

Vancouver

Rogosnitzky M, Berkowitz E, Jadad AR. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. JMIRx Med. 2020. doi:10.2196/19583

BibTeX
@article{Rogosnitzky2020,
  author = {Rogosnitzky, Moshe and Berkowitz, Esther and Jadad, Alejandro R},
  title = {No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19},
  journal = {JMIRx Med},
  year = {2020},
  doi = {10.2196/19583}
}
Kostenlos starten →